Water loss in horticultural products. Modelling, data analysis and theoretical considerations

The water loss of individual fruit (melon, plum and mandarin) was analysed using the traditional diffusion based approach and a kinetic approach. Applying simple non linear regression, both approaches are the same, resulting in a quite acceptable analysis. However, by applying mixed effects non linear regression analysis, explicitly including the variation over the individuals, the kinetic approach was found to reflect the processes occurring during mass loss better than the diffusion approach. All the variation between the individuals in a batch could be attributed to the initial mass or size of the individuals. The fraction of the fruit mass that is available for transpiration is the key item in the water loss process, rather than the skin resistance and fruit area. Obtained explained parts are well over 99%

Fondaparinux in the initial and long-term treatment of venous thromboembolism

Background: Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice. Methods: We used the Registro Informatizado de Enfermedad Tromboembólica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular- weight heparin (LMWH) in those with cancer Results Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p < 0.05). Conclusions: An unexpected high rate of major bleeding was observed in non-cancer patients treated with longterm fondaparinux. Our small sample does not allowto derive relevant conclusions on the use of fondaparinux in cancer patients